Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ. Majumdar AK, et al. Among authors: panebianco d. J Clin Pharmacol. 2006 Mar;46(3):291-300. doi: 10.1177/0091270005283467. J Clin Pharmacol. 2006. PMID: 16490805 Clinical Trial.
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Blum RA, et al. Among authors: panebianco d. Clin Ther. 2003 May;25(5):1407-19. doi: 10.1016/s0149-2918(03)80128-5. Clin Ther. 2003. PMID: 12867217 Review.
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE. Stoch SA, et al. Among authors: panebianco d. Cancer Chemother Pharmacol. 2011 Jun;67(6):1313-21. doi: 10.1007/s00280-010-1421-y. Epub 2010 Aug 24. Cancer Chemother Pharmacol. 2011. PMID: 20734049 Clinical Trial.
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA. McCrea JB, et al. Among authors: panebianco dl. Clin Pharmacol Ther. 2003 Jul;74(1):17-24. doi: 10.1016/S0009-9236(03)00066-3. Clin Pharmacol Ther. 2003. PMID: 12844131 Clinical Trial.
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. Majumdar AK, et al. Clin Pharmacol Ther. 2003 Aug;74(2):150-6. doi: 10.1016/S0009-9236(03)00123-1. Clin Pharmacol Ther. 2003. PMID: 12891225 Clinical Trial.
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
Depré M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P, Petty KJ, Majumdar A, Crumley T, Panebianco D, Bergman A, de Hoon JN. Depré M, et al. Among authors: panebianco d. Eur J Clin Pharmacol. 2005 Jul;61(5-6):341-6. doi: 10.1007/s00228-005-0907-8. Epub 2005 Jun 28. Eur J Clin Pharmacol. 2005. PMID: 15983826 Clinical Trial.
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S. Nygren P, et al. Among authors: panebianco d. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16. doi: 10.1007/s00280-004-0946-3. Epub 2005 Feb 19. Cancer Chemother Pharmacol. 2005. PMID: 15723220 Clinical Trial.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K, Wagner JA. Krishna R, et al. Among authors: panebianco d. Br J Clin Pharmacol. 2009 Oct;68(4):535-45. doi: 10.1111/j.1365-2125.2009.03465.x. Br J Clin Pharmacol. 2009. PMID: 19843057 Free PMC article. Clinical Trial.
80 results